Biocon Biologics' New mAbs Facility Receives EU GMP Certification for bBevacizumab

Biocon Biologics' integrated, multi-product, monoclonal antibodies (mAbs) Drug Substance manufacturing facility (B3) at Biocon Park, Bengaluru, has received a Certificate of GMP Compliance for an additional product, biosimilar Bevacizumab, from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.

"This approval reflects Biocon Biologics' compliance with the highest international regulatory standards and enables the Company to continue addressing the needs of patients in the EU through its high-quality products.

"This (B3) facility, which is one of India's largest monoclonal antibodies (mAbs) manufacturing facilities, had received the EU GMP Certification for manufacturing biosimilar Trastuzumab last year. It was also awarded the 'Facility of the Year Award' (FOYA) with an 'Honourable Mention', by the International Society for Pharmaceutical Engineering (ISPE) in 2021"- Company Spokesperson.

Shares of Biocon Limited was last trading in BSE at Rs. 232.75 as compared to the previous close of Rs. 232.75. The total number of shares traded during the day was 132429 in over 1988 trades.

The stock hit an intraday high of Rs. 233.85 and intraday low of 229.40. The net turnover during the day was Rs. 30705564.00.

Source : Equity Bulls

Keywords

BioconBiologics INE376G01013 mAbs BioconPark GMPCompliance